Venous Thrombosis
Conditions
Interventions
This is a controlled clinical trial, one blinded. A total of 200 patients who meet the eligibility criteria will be randomly allocated to the intervention group (ASA + Rivaroxaban 2.5 mg twice a day)
Sponsors
Hospital das Clínicas da Universidade Federal de Pernambuco
Hospital das Clínicas da Universidade Federal de Pernambuco
Eligibility
Inclusion criteria
Inclusion criteria: Adult participants, with no age limit; regardless of gender; patients with threatening ischemia of the limb and with a proposal for limb revascularization, either by angioplasty or by bypass surgery, at the Vascular Surgery Service of the Hospital das Clínicas of the Federal University of Pernambuco, a branch of the Brazilian Hospital Services Company (HC/EBSERH – UFPE) and sign the free and informed consent form (TCLE)
Exclusion criteria
Exclusion criteria: Patients who present a symptomatic venous thromboembolism (VTE) event during hospitalization will be excluded, they will need full anticoagulation and no longer prophylactic; patients who have any contraindications to the use of Rivaroxaban; do not return for the 30th post-operative day consultation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the incidence of Deep Vein Thrombosis in the post-hospital discharge segment of patients undergoing limb salvage surgery using standard treatment versus Rivaroxaban in an arterial dose plus acetylsalicylic acid. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the incidence of bleeding with the use of Rivaroxaban in an arterial dose plus acetylsalicylic acid, in the postoperative period of limb salvage surgery. | — |
Countries
Brazil
Contacts
Public ContactGabriela Buril
Hospital das Clínicas da Universidade Federal de Pernambuco
Outcome results
None listed